Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News |  Product Profiles: Targeted Cancer Therapies - Patient selection driving novel drug approvalsNew Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
By: Fast Market Research, Inc. Scope * Includes targeted cancer therapy drug profiles and development overviews detailing the companies involved and the clinical data that led to approvals * Includes SWOT analysis of each brand in the targeted cancer therapies class * Overview of each brands positioning in its marketed indications relative to its competitors and in terms of its ability to meet unmet needs * Analysis of the clinical and commercial attractiveness of the targeted cancer therapies ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Highlights As the understanding of the molecular pathogenesis of cancer is improving, companies are increasingly selecting molecularly defined patient populations in the development of novel targeted therapies. The rising incidence of cancer is continuing to drive high R&D activity in oncology. As a result, a number of new targeted therapies have entered the cancer market in the past two years. In 2012, five drugs have been approved by the US Food and Drug Administration (FDA). In the period 2011-2012, a number of important developments took place in three of the 'Big Four' tumor types- breast, colorectal (CRC) and NSCLC. Reasons to Get this Report * Access detailed information about the drugs that make up the most lucrative class in the oncology market * Understand the key factors that led to the success of some targeted cancer therapy brands and the issues which have hindered the uptake of others * Understand how the targeted cancer therapies market will change in the future as developers target niche indications Partial Table of Contents: OVERVIEW * Catalyst * Summary EXECUTIVE SUMMARY * Strategic scoping and focus * Datamonitor key findings * Related reports PRODUCT OVERVIEW * Targeted cancer therapy brands MARKETED PRODUCT PROFILES * Adcetris (brentuximab vedotin; Seattle Genetics/Takeda) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Afinitor (everolimus; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Arzerra (ofatumumab; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Avastin (bevacizumab; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Caprelsa (vandetanib; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Erbitux (cetuximab; Eli Lilly/Bristol- * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Erivedge (vismodegib; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Gleevec (imatinib; Novartis) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Herceptin (trastuzumab; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Inlyta (axitinib; Pfizer) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Iressa (gefitinib; AstraZeneca) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Istodax (romidepsin; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Kyprolis (carfilzomib; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Nexavar (sorafenib; Bayer Schering/Onyx) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Perjeta (pertuzumab; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Revlimid (lenalidomide; * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Rituxan (rituximab; Biogen Idec/Roche/Chugai/ * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Sprycel (dasatinib; Bristol-Myers Squibb) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Sutent (sunitinib; Pfizer) * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Tarceva (erlotinib; OSI Pharmaceuticals/ * Drug profile * Development overview * SWOT analysis * Product positioning * Clinical and commercial attractiveness * Tasigna (nilotinib; Novartis) * Drug profile * Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number